Pfizer Corporation

Neurogen Corporation

Other

University of California

Migenix, Inc.

Pfizer Products Inc.

Spiros Liras

Martin Patrick Allen

Benjamin A Thuma

Vincent Mascitti

Alan J Hutchison

Jun Yuan

Kevin S Currie

Scott A Mitchell

George D Maynard

Pamela Ann Albaugh

Yuhpyng Liang Chen

Robert L Rosati

Linda M Gustavson

Guolin Cai

George P Luke

Stanton F McHardy

Kyungae Lee

Manuka Ghosh

Guiying Li

Nian Liu

Barbara Eileen Segelstein

Ling Hong Xie

Jennifer A Doudna

Soumitra S Ghosh

Brian Thomas O'Neill

Jotham Wadsworth Coe

Yazhong Pei

John M Peterson

Christopher John O'Donnell

Thomas Allen Chappie

Xiao-Qing Tang

John Michael Humphrey

Michael K Ahlijanian

Steven D Heck

William Michael Whalen

Romain Rouet

Benjamin Thuma

Stanton Furst Mchardy

Steven Donald Heck

Vinod Singh

Xie Ling Hong

The present application provides compounds, compositions, uses thereof for the treatment of diseases, conditions and/or disorders, and uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.

Tissue-specific genome engineering using CRISPR-Cas9

Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents. 

Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR

This invention relates to benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds, all of which may be described by of Formula I. The invention is particularly related to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABAreceptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. Novel processes for preparing compounds of Formula I are disclosed. This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes for the localization of GABAreceptors in tissue sections.

Benzimidazole and pyridylimidazole derivatives

The invention provides compounds of Formula I:  wherein R, R, R, R, R, R, Rand A are as defined. Compounds of formula I have activity inhibiting production of A&#x3b2;-peptide. The invention also provides pharmaceutical compositions and methods for treating diseases, for example Alzheimer's disease, in mammals comprising compounds of Formula I.

Pyrazole compounds for treatment of neurodegenerative disorders

The present invention provides a compound having the structure of formula I: wherein Ris hydrogen, (C&#x2013;C) alkyl, unconjugated (C&#x2013;C) alkenyl, benzyl, YC(&#x2550;O)(C&#x2013;C) alkyl or &#x2014;CHCH&#x2014;O&#x2014;(C&#x2013;C) alkyl; X is CHor CHCH; Y is (C&#x2013;C) alkylene; Z is (CH), CF, or C(&#x2550;O), where m is 0, 1 or 2; Rand Rare selected independently from hydrogen, halogen, &#x2014;(C&#x2013;C) alkyl optionally substituted with from 1 to 7 halogen atoms, and &#x2014;O(C&#x2013;C) alkyl optionally substituted with from 1 to 7 halogen atoms, or Rand Reach together with the atom to which it is connected independently form C(&#x2550;O), S&#x2192;O, S(&#x2550;O), or N&#x2192;O; and is a 5- to 7-membered monocyclic heteroaryl group selected from pyridinyl, pyridone, pyridazinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, cinnolinyl, triazinyl, oxadiazolyl, thiadiazolyl and furazanyl groups.

Heteroaryl fused azapolycyclic compounds

This invention relates to benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds, all of which may be described by of Formula I  The invention is particularly related to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABAreceptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. Novel processes for preparing compounds of Formula I are disclosed. This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes for the localization of GABAreceptors in tissue sections.

The invention pertains to substituted quinazoline and isoquinoline compounds that serve as effective phosphodiesterase (PDE) inhibitors. In particular, the invention relates to said compounds which are selective inhibitors of PDE-10. The invention also relates to intermediates for preparation of said compounds; pharmaceutical compositions comprising said compounds; and the use of said compounds in a method for treating certain central nervous system (CNS) or other disorders.

Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline

The invention provides compounds of Formula I: wherein R, R, R, R, R, R, R, and A are as defined. Compounds of formula I have activity inhibiting production of A&#x3b2;-peptide. The invention also provides pharmaceutical compositions and methods for treating diseases, for example Alzheimer's disease, in mammals comprising compounds of Formula I.

The subject invention provides a compound of the formula I, wherein X, Q, n, R, R, R, R, R, R, R, R, R, and Rare as defined. Compounds of formula I have activity as opioid receptor antagonists. The subject invention furthermore provides for pharmaceutical compositions and therapeutic methods comprising compounds of formula I.

3-azabicyclo[3.1.0]hexane derivatives

Compounds which have utility in the treatment of conditions associated with altered mitochondrial function. The compounds have the following structure (I):including stereoisomers, prodrugs, and pharmaceutically acceptable salts thereof, wherein R, R, R, R, Rand Rare as defined herein. Pharmaceutical compositions containing a compound of structure (I), as well as methods relating to the use thereof, are also disclosed.

Ligands of adenine nucleotide translocase (ANT) and compositions and methods related thereto

4,4-biarylpiperidine derivatives

Growing community of inventors

Stonington, CT, United States of America

Spiros Liras